The estimated Net Worth of Andrew D. Jones is at least $61.1 mil dollars as of 3 December 2021. Mr. Jones owns over 45,455 units of Novabay Pharmaceuticals Inc stock worth over $61,092 and over the last 4 years he sold NBY stock worth over $0. In addition, he makes $0 as Chief Financial Officer y Treasurer at Novabay Pharmaceuticals Inc.
Sign up
Mr. Jones NBY stock SEC Form 4 insiders trading
Andrew has made over 1 trades of the Novabay Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 45,455 units of NBY stock worth $20,000 on 3 December 2021.
The largest trade he's ever made was buying 45,455 units of Novabay Pharmaceuticals Inc stock on 3 December 2021 worth over $20,000. On average, Andrew trades about 9,091 units every 0 days since 2020. As of 3 December 2021 he still owns at least 127,461 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Mr. Jones stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Jones biography
Andrew Jones serves as Chief Financial Officer, Treasurer of the Company. He served as the Vice President of Finance of MyoScience, Inc., a commercial stage company that produced disposable pain management devices, from July 2017 until its acquisition by Pacira BioSciences, Inc. (Nasdaq: PCRX) in August 2019, during which time he was responsible for all financial, accounting, investor relations and risk management functions as well as leading debt and equity fundraising. Mr. Jones has served as Controller for various public and private life sciences companies including Armetheon, Inc. (May 2015 to July 2017), Asante Solutions, Inc. (Oct. 2014 to May 2015) and Genelabs Technologies, Inc. (then, Nasdaq: GNLB) (2005 to 2009) and began his career with PriceWaterhouseCoopers. Mr. Jones received a B.S. degree in Business Administration from the University of Washington in Seattle.
How old is Andrew Jones?
Andrew Jones is 50, he's been the Chief Financial Officer y Treasurer of Novabay Pharmaceuticals Inc since 2020. There are 5 older and 4 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.
What's Andrew Jones's mailing address?
Andrew's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at Novabay Pharmaceuticals Inc
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
What does Novabay Pharmaceuticals Inc's logo look like?
Complete history of Mr. Jones stock trades at Novabay Pharmaceuticals Inc y Eyenovia Inc
Novabay Pharmaceuticals Inc executives and stock owners
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Justin M. Hall Esq.,
Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director -
Justin Hall,
President, Chief Executive Officer, Director -
Andrew Jones,
Chief Financial Officer, Treasurer -
Swan Sit,
Independent Director -
Yenyou Zheng,
Independent Director -
Paul Freiman,
Independent Director -
Mijia Wu,
Director -
Xinzhou Li,
Director -
Dr. Jeffrey Kunin M.D.,
Pres of DERMAdoctor -
Dr. Audrey Kunin M.D.,
Chief Product Officer -
Yongxiang Zheng,
Director -
Julie Garlikov,
Director -
Wang Xu,
NEO - Sr Mgr and Controller -
Lewis J Stuart,
Chief Commercial Officer -
Yanbin Liu,
Director -
Jason Philip Raleigh,
Interim CFO and Treasurer -
Xiaoyan Liu,
Director -
Gail J Maderis,
Director -
Todd Erik Zavodnick,
Director -
Pharma (Singapore) Pte. Ltd...,
10% owner -
T. Alex Mc Pherson,
Director -
Thomas J Paulson,
Chief Financial Officer -
Yonghao Ma,
Director -
Jian Ping Fu,
10% owner -
Massimo Radaelli,
Director -
Mark M Sieczkarek,
Director -
Pharma (Hong Kong) Co Ltd P...,
10% owner -
John Joseph Mc Govern,
Int Pres, CEO, CFO & Treasurer -
John James O'reilly,
Chief Financial Officer -
Colin Scott,
VP, Clinical Research & Dev't -
Keith R Bley,
SVP Product Development -
Pioneer Pharma Holdings Ltd...,
10% owner -
Roy J Wu,
SVP Bus & Corp Development -
David W. Stroman,
SVP, Ophthalmic Product Devt. -
Tony D.S. Wicks,
Director -
Anthony Dailley,
Director -
Robert R. Tufts,
Director -
Charles Cashion,
Director -
Behzad Khosrovi,
VP, Research & Dev't -
Ramin Najafi,
Chief Executive Officer -
Area Pioneer Pharma Co., Lt...,
10% owner -
Ramin Najafi Family Trust D...,
Chief Executive Officer -
Mark Brian Anderson,
CSO -
Harry F Jr Hixson,
Director -
Russell A. Hoon,
Senior Vice President -
Xiaopei Wang,
-
Jeffrey Kunin,
President, DERMAdoctor, LLC -
Audrey Kunin,
Chief Product Officer